Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Core Viewpoint - Shah Capital has called on Novavax's board to consider selling the biotech company due to a third consecutive year of poor performance in the rollout of its COVID-19 vaccine [1] Company Summary - Novavax has faced challenges in effectively distributing its COVID-19 vaccine for three years in a row, prompting concerns from investors [1]